Stock listing
NASDAQ:RTSN Retension Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Retension Pharmaceuticals, Inc.
Follow Retension Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:RTSN
$10.51 USD -2.50 (-19.2%)
Close on Nov 20, 2026
- Day range
- $9.23 – $13.10 USDNov 20, 2026
- Volume
- 162,742 sharesNov 20, 2026
- Market cap
- $87.57M USDAt the close on Nov 20, 2026 · price × 8.33M shares outstanding
- Traded on an average day
- $1.74M USDMedian day 103,606 shares · 1 day with no trades · last 3 months, Oct 8, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RTSN · Home | $10.51 USD | -2.50 (-19.2%) | 162,742 | $12.80 | $13.10 | $9.23 | $13.01 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Oct 8, 2026 – Nov 20, 2026 · NASDAQ:RTSN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $10.51 | -2.50 | -19.2% | $12.80 | $13.10 | $9.23 | 162,742 | |
| $13.01 | -0.88 | -6.3% | $13.86 | $13.92 | $12.61 | 54,566 | |
| $13.89 | +2.48 | +21.7% | $11.45 | $14.16 | $11.45 | 108,911 | |
| $11.41 | -0.05 | -0.4% | $11.37 | $11.88 | $10.25 | 44,129 | |
| $11.46 | -0.81 | -6.6% | $12.20 | $12.34 | $10.25 | 320,854 | |
| $12.27 | +0.02 | +0.2% | $12.30 | $12.70 | $11.37 | 125,000 | |
| $12.25 | +0.10 | +0.8% | $11.79 | $12.40 | $11.63 | 94,400 | |
| $12.15 | +0.13 | +1.1% | $11.89 | $12.40 | $11.59 | 91,500 | |
| $12.02 | -0.37 | -3.0% | $12.16 | $12.77 | $11.03 | 248,100 | |
| $12.39 | +1.35 | +12.2% | $10.96 | $12.83 | $10.31 | 306,400 | |
| $11.04 | +0.32 | +3.0% | $10.62 | $11.19 | $10.54 | 29,400 | |
| $10.72 | -0.88 | -7.6% | $11.33 | $11.80 | $10.43 | 114,400 | |
| $11.60 | -0.19 | -1.6% | $12.18 | $12.80 | $11.40 | 153,000 | |
| $11.79 | +0.49 | +4.3% | $11.07 | $12.25 | $11.07 | 81,500 | |
| $11.30 | -0.06 | -0.5% | $11.44 | $13.03 | $11.20 | 71,300 | |
| $11.36 | -0.47 | -4.0% | $11.76 | $11.76 | $10.85 | 58,700 | |
| $11.83 | -1.26 | -9.6% | $12.95 | $12.97 | $11.30 | 45,100 | |
| $13.09 | -0.43 | -3.2% | $13.44 | $13.90 | $12.19 | 67,300 | |
| $13.52 | -0.72 | -5.1% | $14.40 | $14.60 | $12.70 | 75,300 | |
| $14.24 | -1.01 | -6.6% | $15.13 | $15.82 | $14.24 | 47,200 | |
| $15.25 | -0.25 | -1.6% | $15.85 | $16.29 | $14.59 | 77,900 | |
| $15.50 | +0.50 | +3.3% | $14.81 | $16.00 | $14.07 | 121,100 | |
| $15.00 | -1.18 | -7.3% | $16.18 | $18.19 | $14.29 | 110,600 | |
| $16.18 | -0.15 | -0.9% | $16.53 | $17.40 | $15.11 | 98,300 | |
| $16.33 | +2.26 | +16.1% | $14.14 | $18.64 | $14.10 | 267,200 | |
| $14.07 | +1.86 | +15.2% | $12.21 | $14.97 | $12.17 | 208,900 | |
| $12.21 | +0.57 | +4.9% | $11.56 | $12.86 | $11.56 | 131,000 | |
| $11.64 | +0.01 | +0.1% | $11.63 | $12.25 | $11.00 | 77,200 | |
| $11.63 | +0.31 | +2.7% | $11.83 | $12.50 | $11.41 | 137,600 | |
| $11.32 | +0.79 | +7.5% | $10.88 | $11.79 | $10.16 | 173,900 | |
| $10.53 | -1.47 | -12.3% | $10.00 | $11.60 | $9.66 | 789,200 | |
| $12.00 | — | — | $12.00 | $12.00 | $12.00 | 0 |
- Ticker
- NASDAQ:RTSN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Latest news
Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 18, 2026
Closed $13.89 (+21.7%) on Nov 18, 2026
Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 5, 2026
Closed $10.72 (-7.6%) on Nov 5, 2026
Retension Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in the last 12 months · 2 in all · newest Nov 18, 2026 · oldest 2026
Where Retension Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RTSN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:RTSN | BOATS | United States | USD |
| Frankfurt:TL4 | Frankfurt | Germany | EUR |
| Hamburg:TL4 | Hamburg | Germany | EUR |
| Munich:TL4 | Munich | Germany | EUR |
Valuation
Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $78.38M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Retension Pharmaceuticals, Inc. · NASDAQ:RTSN | US$87.57M | US$78.38M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Infant Bacterial Therapeutics AB Class B · OMXSTO:IBT_B | US$88.42M | US$77.79M | n/a | n/a | n/a | 17.0× | n/a | 0.0× | n/a |
| Bio Solution Co., Ltd. · KRX:086820 | US$88.40M | US$79.76M | 137× | 6.2× | n/a | 2.9× | 5.0% | 0.0× | n/a |
| Y-Biologics Inc. · KRX:338840 | US$87.59M | US$70.94M | n/a | 30.1× | n/a | 6.8× | n/a | 0.9× | n/a |
| Cumberland Pharmaceuticals Inc. · NASDAQ:CPIX | US$87.57M | US$11.59M | 1.3× | 0.5× | n/a | 1.2× | 273.7% | 0.1× | 0.72 |
| Equillium, Inc. · NASDAQ:EQ | US$87.26M | US$34.71M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.31 |
| Upstream Bio, Inc. · NASDAQ:UPB | US$87.15M | −US$119.4M | n/a | −41.6× | n/a | 0.4× | n/a | 0.0× | 1.95 |
| Senhwa Biosciences Inc · TPEX:6492 | US$86.77M | US$67.44M | n/a | 2,117× | n/a | 4.6× | n/a | 0.0× | n/a |
| Bioceltix SA · GPW:BCX | US$86.32M | US$72.37M | n/a | n/a | n/a | 5.6× | n/a | 0.0× | n/a |
| Perspective Therapeutics, Inc. · AMEX:CATX | US$86.05M | −US$114.1M | n/a | −570× | n/a | 0.3× | n/a | 0.0× | 1.47 |
| Pharmosa Biopharm Inc. · TPEX:6875 | US$86.04M | US$62.27M | n/a | 38.5× | n/a | 2.1× | −658.1% | 0.1× | n/a |
| Median of the others | US$87.21M | US$64.86M | 69.1× | 6.2× | 2.5× | 5.0% | 0.0× | 1.39 |
Forecasts
3 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 51.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.60 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Eric Keller | Chief Executive Officer, Co-Founder & Chairman |
| Alex Schwartz | Chief Financial Officer |
| Sabine Bisson | Chief Operating Officer |
| Kevin Schutz | Vice President, Regulatory Affairs |
| LeAnne Bloedon | Executive Vice President, Clinical Development and Operations |
| Alison D. Schecter | Chief Medical Officer |
| Paul Sweetnam | Chief Scientific Officer & Co-Founder |
Board
| Director | Role |
|---|---|
| Eric Keller | Chief Executive Officer, Co-Founder & Chairman |
| Donald Olds | Director |
| Franklin Berger | Director |
| Pavan Cheruvu | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 18, 2026 | +14.0% |
IPO
Priced at US$12.00 a share on Oct 8, 2026.
- Price
- US$12.00 a share
- Shares offered
- 3,750,000 shares of common stock
- Offering size
- US$45 million
- Underwriters' option
- Up to 562,500 more shares
- Listing
- RTSN on the Nasdaq Capital Market
- Underwriters
- Leerink Partners, Guggenheim Securities, Oppenheimer & Co., Titan Partners · In the order on the cover
- Shares delivered
- On or about Oct 13, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 17, 2026 |
| Filed publicly | Sep 18, 2026 |
| Amended twice | Newest Oct 7, 2026 |
| Shares registered with an exchange | Oct 8, 2026 |
| Declared effective by the SEC | Oct 8, 2026 |
| Final prospectus, with the price | Oct 9, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 9, 2026 |
| EFFECT · Notice that a registration is effective | Oct 8, 2026 |
| S-1MEF · Registration of more shares for the same offering | Oct 8, 2026 |
| CERT · Exchange's certificate of listing | Oct 8, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 8, 2026 |
| S-1/A · Registration statement, amended | Oct 7, 2026 |
| S-1/A · Registration statement, amended | Oct 5, 2026 |
| S-1 · Registration statement | Sep 18, 2026 |
| DRS/A · Draft registration statement, amended | Aug 14, 2026 |
| DRS/A · Draft registration statement, amended | Jun 16, 2026 |
All 12 filings
| Filing | Filed |
|---|---|
| DRS/A · Draft registration statement, amended | May 1, 2026 |
| DRS · Draft registration statement | Feb 17, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 9, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Research and development | 5.11M | 1.30M |
| Selling, general and administrative | 1.77M | 976.4K |
| Operating income | -6.88M | -2.28M |
| Income before tax | -6.30M | -1.91M |
| Net income | -6.30M | -1.91M |
| Earnings per share, basic | -0.76 | -0.23 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 18.9M | 8.19M |
| Current assets | 21.4M | 8.37M |
| Total assets | 21.4M | 8.37M |
| Accounts payable | 775.9K | 194.4K |
| Current liabilities | 912.2K | 277.0K |
| Total liabilities | 29.2M | 10.1M |
| Shareholders' equity | -7.78M | -1.73M |
| Shares outstanding | 8.33M | 8.33M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -7.78M | -1.76M |
| Capital spending | 0 | 0 |
| Free cash flow | -7.78M | -1.76M |
| Cash from financing | 18.5M | 3.61M |
| Change in cash | 10.7M | 1.86M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 18, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 18, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 22, 2026 | Management or board change | SEC |
| 3 · Initial statement of ownership | Oct 16, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 15, 2026 | Big-stake notice | SEC |
All 47 filings
Cap table
Built by 6ix from Retension Pharmaceuticals, Inc.’s releases
- Common shares
- 8,331,599
- Fully diluted
- 8,331,599
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 8,331,599 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 8,331,599 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Franklin Berger Other companies: Atea Pharmaceuticals, Inc. (Director · Since at least Oct 29, 2020); ESSA Pharma Inc (Director · Since at least Oct 1, 2020); Kezar Life Sciences, Inc. (Director · Since at least Jun 20, 2018); Rain Oncology Inc (Director · Apr 22, 2021 – Jan 26, 2024 · Past); Atreca Inc (Director · Jun 19, 2019 – Jun 13, 2023 · Past); Tocagen Inc (Director · Apr 12, 2017 – Oct 4, 2019 · Past); Kineta Inc. (Director · Feb 10, 2016 – Jun 29, 2020 · Past); Immune Design Corp (Director · Jul 23, 2014 – Apr 2, 2019 · Past); Five Prime Therapeutics Inc (Director · Sep 17, 2013 – Apr 16, 2021 · Past); Lineage Cell Therapeutics, Inc. (Director · May 13, 2013 – Aug 20, 2013 · Past); Emisphere Technologies Inc (Director · May 15, 2009 – May 15, 2009 · Past); Seagen Inc (Director · May 19, 2006 – Feb 21, 2014 · Past) | Director · Since at least Oct 13, 2026 |
| Pavan Cheruvu Other companies: Amanat Acquisition Corp (Chief Executive Officer, Director · Since at least May 18, 2026); Sio Gene Therapies Inc (Chief Executive Officer, Director · Feb 11, 2018 – Dec 8, 2021 · Past) | Director · Since at least Nov 5, 2026 |
| Donald Olds Other companies: Grace Therapeutics, Inc. (Director · Apr 1, 2020 – Aug 31, 2023 · Past) | Director · Since at least Oct 13, 2026 |
| Michael J Berendt Other companies: Waters Corporation (Director · May 15, 2013 – Aug 13, 2021 · Past) | Director · Since at least Oct 13, 2026 |
| Alex Schwartz | Chief Financial Officer · Since at least Nov 4, 2026 |
| Alison D. Schecter | Chief Medical Officer · Since at least Nov 4, 2026 |
| Eric Keller | CHIEF EXECUTIVE OFFICER, Director · Since at least Oct 13, 2026 |
| Kevin Schutz | Vice President, Regulatory Affairs · Since at least Nov 4, 2026 |
| LeAnne Bloedon | Executive Vice President, Clinical Development and Operations · Since at least Nov 4, 2026 |
| Paul Sweetnam | CHIEF SCIENTIFIC OFFICER · Since at least Oct 13, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Sabine Bisson | CHIEF OPERATING OFFICER · Since at least Oct 13, 2026 |
Log in to ask 6ix AI your own questions about Retension Pharmaceuticals, Inc.